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The new policy from the National Institutes of Health to encourage grant applicants to consider studying both
females and males in preclinical biological experiments has been met with support and opposition. Here, we will
discuss implications of preclinical studies of sex differences on clinical research.
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Letters to the Editor
It is now over a year since the announcement of a new
National Institutes of Health (NIH) policy to encourage
applicants to consider studying both females and males
in preclinical biological experiments. The policy would
prevent researchers from assuming no sex difference or
ignoring one sex entirely [1]. Implementation of this pol-
icy is now beginning. It has been supported by some [2],
while others oppose [3]. Should all researchers be ex-
pected to assess for sex differences [4]? Here, I offer a
clinical perspective.
Sex differences in health and disease are numerous.
There are sex differences in neurodegenerative, cardio-
vascular, and autoimmune diseases, to name a few [5].
Clinical observations of sex differences in disease should
be viewed as precious clues in the search for new treat-
ments to protect from disease, since they are naturally
occurring disease modifiers [6]. Preclinical research on
animals is essential for disentangling various mecha-
nisms underlying sex differences in human diseases, re-
vealing candidate targets for ultimate translation back to
humans in a “bedside to bench to bedside” approach.
We have recently employed this strategy to investigate
the protective effects of an estrogen treatment in women
with multiple sclerosis [7].
Arguments against basic biological research on sex dif-
ferences in animals have included the idea that cells
studied in the culture dish do not function like cells in
the human body and that mice differ from humans [3].
However, those limitations are true for all preclinical re-
search, not just sex differences. No preclinical model
perfectly simulates all aspects of human disease. Each
model is chosen based on a specific question, and sev-
eral different models are used to provide comprehensive
insight. Why should the study of the biology of sex dif-
ferences be held to a different standard?
Another rationale for not doing biological sex differ-
ences research has been that there are gender-related so-
cial factors in humans that are poorly modeled in
preclinical research [3]. Most clinical observations in
humans are the result of both biological and social fac-
tors, nature and nurture. There are social and cultural
differences affiliated with age and race. Does this pre-
clude the study of biological effects of aging or race? No.
Sex, age, and race are each important variables that im-
pact disease, and understanding both the biological and
social factors is needed for optimal treatments in each
population.
Let us now look beyond the first step the NIH has
proposed that encourages researchers to consider sex as
a biological variable in their systems. In the years ahead,
this will result in many new observations of sex differ-
ences. When you look, you find. But to show that sex
differences exist is the beginning, not the end. A second
step is needed. Support for research to understand the
mechanistic basis for observed sex differences will be re-
quired to capitalize on initial observations and translate
them back to human disease. If step one is taken without
step two, a bottleneck of observations regarding sex
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differences will accumulate. Both steps are needed for
ultimate translation back to the clinic.
In summary, an inconvenient truth for some seems to
be that biological sex differences exist in many systems.
Speaking as a feminist, sex differences do not imply in-
equality of the sexes. Speaking as a scientist, knowledge
is always the path forward. Speaking as a physician, how
can we justify ignoring a major disease modifier to pa-
tients? Rather, we must embrace the study of sex differ-
ences without political bias or fear of misinterpretation
in the pursuit of health for man- and womankind.
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